Related Experiment Video
Updated: Feb 15, 2026
Modeling Spontaneous Metastatic Renal Cell Carcinoma mRCC in Mice Following Nephrectomy
Published on: April 29, 2014
[Immunotherapy in renal cell carcinoma: A booming clinical research]
1Unité transversale de thérapeutiques innovantes en oncologie médicale (UTTIOM), centre hospitalier universitaire d'Angers, 4, rue Larrey, 49933 Angers, France.
Context:
Nivolumab, an anti-PD1 immune control point inhibitor, is the first treatment that has improved the overall survival of patients after first-line metastatic renal cell carcinoma in 2015. Over the past two years, a large number of trials on these treatments and the interest of associations are being evaluated.
Objective:
In this article, we propose to summarize the clinical development of checkpoint inhibitors to assess the direction of clinical research in this area.
Documentary Source:
A systematic review of the literature was performed in PubMed/Medline database and Meeting Library Asco by searching for articles in French or English published on immunotherapy in renal cell carcinoma. The research was limited to abstracts and articles published from 2014 to 2017.
Selection Of Trials:
We identified 349 publications and abstracts and selected 17 references from prospective studies.
Results:
Recent data on checkpoint inhibitors, as well as their combination with tyrosine kinase inhibitors or with anti-angiogenic agents or with indoleamine 2, 3-dioxygenase 1 in renal cell carcinoma and the latest advances in vaccine therapy have been reported.
Conclusion:
In 2017, immunotherapy combined with other treatments is likely to lead to a paradigm shift in the clinical management of patients. The combination of nivolumab and ipilimumab in the first line will revolutionize the therapeutic management of patients with metastatic renal cell carcinoma.
Insights
Nivolumab, an anti-PD1 immune checkpoint inhibitor, improved survival in metastatic renal cell carcinoma. Future research focuses on combining immunotherapies for better patient outcomes.
Area of Science:
- Oncology
- Immunotherapy
- Renal Cell Carcinoma
Background:
- Nivolumab (anti-PD1 inhibitor) demonstrated improved overall survival in first-line metastatic renal cell carcinoma (mRCC) in 2015.
- Significant research interest and clinical trials have emerged evaluating immune checkpoint inhibitors in mRCC.
Purpose of the Study:
- To summarize the clinical development of immune checkpoint inhibitors in renal cell carcinoma.
- To assess the current direction of clinical research in this rapidly evolving field.
Main Methods:
- A systematic literature review was conducted using PubMed/Medline and the ASCO Meeting Library.
- Searched for articles in French or English on immunotherapy for renal cell carcinoma, published between 2014 and 2017.
- Identified 349 publications and abstracts, selecting 17 prospective studies for analysis.
Main Results:
- Recent data highlight checkpoint inhibitors, combinations with tyrosine kinase inhibitors, anti-angiogenic agents, and indoleamine 2,3-dioxygenase 1 inhibitors in mRCC.
- Advances in vaccine therapy for renal cell carcinoma were also reported.
Conclusions:
- Immunotherapy combined with other treatments is poised to shift clinical management paradigms in mRCC by 2017.
- The combination of nivolumab and ipilimumab in first-line treatment is expected to revolutionize therapeutic strategies for metastatic renal cell carcinoma.
More Related Videos
05:36Comparing Metastatic Clear Cell Renal Cell Carcinoma Model Established in Mouse Kidney and on Chicken Chorioallantoic Membrane
Published on: February 8, 2020
06:38A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Related Concept Videos
01:27Tumor Immunotherapy
01:17Factors Affecting Renal Clearance: Renal Impairment
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
01:19Clinical Applications of Epidermal Stem Cells
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...
01:23Renal Clearance
Renal clearance refers to the volume of plasma cleared of a specific substance, such as creatinine, per unit of time. To measure clearance, urine samples are collected over a 24-hour period during each bladder voiding, followed by a single blood sample at the...
01:08Renal Drug Clearance: Comparison Between Renal Excretion Methods
Renal clearance is often associated with the renal glomerular filtration rate (GFR), which represents the rate at which plasma is filtered through the glomeruli in the kidney. When drug reabsorption is minimal and there is no active secretion, renal clearance is closely related to the...